March 2026 in “Skin Appendage Disorders” Belatacept may be a promising treatment for alopecia areata.
6 citations
,
January 1999 in “Dermatology” Alopecia areata is linked to autoimmune antibodies.
26 citations
,
May 2020 in “JCI Insight” Alopecia areata involves specific immune cells, offering potential treatment targets.
6 citations
,
January 2024 in “International Journal of Dermatology” Monoclonal antibodies are often linked to alopecia areata cases.
September 2024 in “Archives of Medical Science” Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.
January 2007 in “Yearbook of Dermatology and Dermatologic Surgery” Certain types of alopecia areata are linked to allergies, autoimmune diseases, and family history.
Certain immune markers and vitamin levels could help diagnose alopecia areata.
June 2015 in “Annals of the Rheumatic Diseases” Managing multiple autoimmune diseases in one patient is very challenging.
January 2020 in “VCU Scholars Compass (Virginia Commonwealth University)” Sex hormone antibodies can help identify male and female contributors in forensic samples.
12 citations
,
February 2023 in “Journal of Personalized Medicine” Type 1 diabetes often occurs with other autoimmune diseases, and personalized treatment based on genetics can improve outcomes.
March 2026 in “Dermatology and Therapy” Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.
June 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Anti-Ku-positive patients often have muscle weakness and autophagy plays a key role in their condition.
Belimumab may cause hair loss in lupus patients.
November 2023 in “Journal of Investigative Dermatology” The study identified key immune cell differences between mild and severe alopecia areata.
3 citations
,
October 2022 in “Journal of Cosmetic Dermatology” CAR is a useful marker for assessing alopecia areata severity.
66 citations
,
July 2010 in “Journal of Proteome Research” Trichohyalin may trigger the immune response causing alopecia areata.
CD28 is a promising target for treating alopecia areata with belatacept.
CD28 is a promising target for treating alopecia areata with belatacept.
10 citations
,
March 2014 in “Scandinavian journal of clinical and laboratory investigation” Malondialdehyde-modified DNA may trigger an immune response in alopecia areata patients.
January 2019 in “Przegląd Dermatologiczny” Patients with one autoimmune disease should be checked for other autoimmune disorders.
A man with four autoimmune diseases suggests a new category for multiple autoimmune syndrome.
54 citations
,
August 1981 in “British Journal of Dermatology” Alopecia areata is linked to reduced T cell function and auto-immunity.
CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.
May 2025 in “Preprints.org” Unique microRNA patterns can help diagnose and treat severe alopecia areata.
September 2024 in “Annals of Dermatology” A new diagnostic model can help better diagnose and understand Alopecia Areata.
April 2023 in “Dermatology practical & conceptual” Some patients with hair loss after mild COVID-19 had positive tests for certain autoantibodies.
June 2024 in “British Journal of Dermatology” Dermatologists vary widely in testing practices for alopecia areata, often exceeding guideline recommendations.
January 2014 in “Repository KITopen (Karlsruhe Institute of Technology)” Autoimmune diseases need combined therapy of tolerance induction and immunosuppression.
May 2023 in “The Journal of Immunology” Alopecia areata involves unique activation of certain immune cells.
July 2024 in “Journal of Investigative Dermatology” Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.